This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• Absolute Neutrophil count ≥ 1500/mm3
• Platelets ≥ 100,000/mm3
• Creatinine ≤ 1.5 mg/dL OR Creatinine Clearance ≥ 45mL/min
No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2 teaspoon of red blood) =< 8 weeks prior to registration
No evidence of intracranial hemorrhage =< 4 weeks prior to registration
Patients who have experienced thromboembolic event within 6 months prior to registration must be on stable therapeutic anticoagulation for at least 4 weeks prior to registration
Vemurafenib taken two times a day for 28 days. Cobimetinib taken for 21 days.
Electrocardiograms (EKG) will be performed at screening and every month for 3 months, then every 3 months while receiving vemurafenib.
Echocardiograms (Echo) of the heart (or MUGA) will be performed at screening and after 1 month of treatment and every 3 months while on cobimetinib.
Brain MRI at screening and every 8 weeks during study treatment, then every 16 weeks after completion of study treatment.
An eye exam is needed every 2 months for one year, then every 6 months while on study drugs, and at the end of treatment with study drugs.